Compare OTTR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTTR | RCUS |
|---|---|---|
| Founded | 1907 | 2015 |
| Country | United States | United States |
| Employees | N/A | 601 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.6B |
| IPO Year | 2009 | 2018 |
| Metric | OTTR | RCUS |
|---|---|---|
| Price | $92.31 | $28.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.90 |
| AVG Volume (30 Days) | 248.7K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $1,299,640,000.00 | $247,000,000.00 |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | $3.83 | $45.62 |
| P/E Ratio | $53.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.15 | $8.84 |
| 52 Week High | $95.00 | $31.74 |
| Indicator | OTTR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 51.38 |
| Support Level | $84.68 | $20.20 |
| Resistance Level | $92.60 | $28.72 |
| Average True Range (ATR) | 2.03 | 1.33 |
| MACD | 0.17 | -0.16 |
| Stochastic Oscillator | 63.91 | 50.83 |
Otter Tail Corp is a U.S. energy company that operates in the electric (produces and sells electricity), manufacturing (fabricates metal components), and plastics segments (pipes for water uses). The company conducts its operations and acquires the majority of its revenue in the U.S. in the states of Minnesota, South Dakota, and North Dakota. The majority of the company's revenue is derived from the Electric segment and commercial customers, although it generates revenue from residential and industrial customers, as well.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.